Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
MIRM | US
2.15
2.42%
Healthcare
Biotechnology
30/06/2024
10/03/2026
90.93
88.05
91.00
87.25
Mirum Pharmaceuticals Inc. a biopharmaceutical company focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals Inc. was incorporated in 2018 and is headquartered in Foster City California.
View LessStrong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
Price Below SMA10D
High Short-term Volatility
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
88.7%1 month
65.2%3 months
54.3%6 months
44.0%-
39.68
8.19
1.38
0.48
-8.85
7.24
-
-88.76M
4.34B
4.34B
-
-31.12
-
107.70
-70.98
17.96
17.44
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
24.95
Range1M
24.95
Range3M
46.05
Rel. volume
1.00
Price X volume
69.90M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Xenon Pharmaceuticals Inc | XENE | Biotechnology | 60.61 | 4.59B | -3.43% | n/a | 1.19% |
| Alkermes plc | ALKS | Biotechnology | 27.74 | 4.57B | -2.50% | 12.40 | 28.66% |
| TG Therapeutics Inc | TGTX | Biotechnology | 29.27 | 4.53B | 0.27% | 34.28 | 63.38% |
| CRISPR Therapeutics AG | CRSP | Biotechnology | 52.8 | 4.50B | -10.17% | n/a | 11.68% |
| Amicus Therapeutics Inc | FOLD | Biotechnology | 14.36 | 4.26B | -0.07% | n/a | 335.08% |
| Erasca Inc. Common Stock | ERAS | Biotechnology | 15.58 | 4.24B | -1.14% | n/a | 11.96% |
| Scholar Rock Holding Corporation | SRRK | Biotechnology | 44.78 | 4.04B | 1.24% | n/a | 50.92% |
| Fluent Inc | COGT | Biotechnology | 36.68 | 4.01B | -0.89% | n/a | 4.87% |
| Ligand Pharmaceuticals Incorporated | LGND | Biotechnology | 212.29 | 3.88B | 1.98% | 45.66 | 0.98% |
| Viking Therapeutics Inc | VKTX | Biotechnology | 34.66 | 3.84B | 3.12% | n/a | 0.12% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Thor Industries Inc | THO | Recreational Vehicles | 84.71 | 4.48B | -1.37% | 23.44 | 27.88% |
| VeriFone Systems Inc | PAY | Building Products & Equipment | 26.02 | 3.24B | 0.93% | 102.46 | 2.10% |
| LCI Industries | LCII | Recreational Vehicles | 126.52 | 3.22B | -1.75% | 25.82 | 77.66% |
| Polaris Industries Inc | PII | Recreational Vehicles | 52.75 | 2.94B | 0.04% | 14.48 | 170.51% |
| Harley-Davidson Inc | HOG | Recreational Vehicles | 18.91 | 2.49B | 0.75% | 7.33 | 218.58% |
| HNI Corporation | HNI | Building Products & Equipment | 40.43 | 1.91B | -2.27% | 22.12 | 76.47% |
| Pitney Bowes Inc | PBI | Building Products & Equipment | 10.59 | 1.90B | -0.75% | n/a | -571.93% |
| ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 13.8 | 1.38B | -1.92% | n/a | 19.46% |
| Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 36.32 | 1.14B | 0.28% | 51.60 | 88.92% |
| Winnebago Industries Inc | WGO | Recreational Vehicles | 34.15 | 988.81M | -3.12% | 22.53 | 56.33% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -8.85 | 0.53 | Cheaper |
| Ent. to Revenue | 7.24 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 8.19 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 54.34 | 72.80 | Lower Risk |
| Debt to Equity | 1.38 | -1.23 | Expensive |
| Debt to Assets | 0.48 | 0.25 | Expensive |
| Market Cap | 4.34B | 3.66B | Par |